{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:26:33Z","timestamp":1786926393769,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Regeneron Pharmacetucials, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10557-019-06852-6","type":"journal-article","created":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T14:27:52Z","timestamp":1549636072000},"page":"69-76","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia"],"prefix":"10.1007","volume":"33","author":[{"given":"Henry N.","family":"Ginsberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaakko","family":"Tuomilehto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh K.","family":"Sanganalmath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Koren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J.","family":"Raal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,8]]},"reference":[{"key":"6852_CR1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.atherosclerosis.2016.09.001","volume":"256","author":"M Arca","year":"2017","unstructured":"Arca M. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): the promises of PCSK9 inhibitors. Atherosclerosis. 2017;256:134\u201345.","journal-title":"Atherosclerosis"},{"issue":"45","key":"6852_CR2","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478\u201390a.","journal-title":"Eur Heart J"},{"issue":"2","key":"6852_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","volume":"9","author":"TA Jacobson","year":"2015","unstructured":"Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1--full report. J Clin Lipidol. 2015;9(2):129\u201369.","journal-title":"J Clin Lipidol"},{"key":"6852_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"253","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Atherosclerosis. 2016;253:281\u2013344.","journal-title":"Atherosclerosis"},{"key":"6852_CR5","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines. J Am Coll Cardiol. 2018.","DOI":"10.1161\/CIR.0000000000000624"},{"issue":"14","key":"6852_CR6","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"DM Lloyd-Jones","year":"2017","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J Am Coll Cardiol. 2017;70(14):1785\u2013822.","journal-title":"J Am Coll Cardiol"},{"issue":"43","key":"6852_CR7","first-page":"2996","volume":"36","author":"JJP Kastelein","year":"2015","unstructured":"Kastelein JJP, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, et al. ODYSSEY FH I and FH II: 78\u00a0week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996\u20133003.","journal-title":"Eur Heart J"},{"issue":"5","key":"6852_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","volume":"30","author":"HN Ginsberg","year":"2016","unstructured":"Ginsberg HN, Rader DJ, Raal FJ, Guyton JR, Baccara-Dinet MT, Lorenzato C, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160\u00a0mg\/dl or higher. Cardiovasc Drugs Ther. 2016;30(5):473\u201383.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"16","key":"6852_CR9","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u201399.","journal-title":"N Engl J Med"},{"issue":"1","key":"6852_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jacl.2016.12.004","volume":"11","author":"JJ Kastelein","year":"2017","unstructured":"Kastelein JJ, Hovingh GK, Langslet G, Baccara-Dinet MT, Gipe DA, Chaudhari U, et al. Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017;11(1):195\u2013203.e4.","journal-title":"J Clin Lipidol"},{"key":"6852_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.atherosclerosis.2016.10.020","volume":"254","author":"M Casula","year":"2016","unstructured":"Casula M, Scotti L, Tragni E, Merlino L, Corrao G, Catapano AL. Drug treatment and adherence of subjects <\u200940\u00a0years with diagnosis of heterozygous familial hypercholesterolemia. Atherosclerosis. 2016;254:172\u20138.","journal-title":"Atherosclerosis"},{"issue":"6","key":"6852_CR12","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.jacl.2017.08.016","volume":"11","author":"JC Defesche","year":"2017","unstructured":"Defesche JC, Stefanutti C, Langslet G, Hopkins PN, Seiz W, Baccara-Dinet MT, et al. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. J Clin Lipidol. 2017;11(6):1338\u201346 e7.","journal-title":"J Clin Lipidol."},{"issue":"6","key":"6852_CR13","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.jacl.2017.09.003","volume":"11","author":"GK Hovingh","year":"2017","unstructured":"Hovingh GK, Raal FJ, Dent R, Stefanutti C, Descamps O, Masana L, et al. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017;11(6):1448\u201357.","journal-title":"J Clin Lipidol."},{"issue":"18","key":"6852_CR14","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"key":"6852_CR15","doi-asserted-by":"crossref","unstructured":"Ray KK, Colhoun H, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner V et al. Alirocumab and cardiovascular outcomes in patients with acute coronary syndrome (ACS) and diabetes\u2014prespecified analyses of ODYSSEY OUTCOMES. Diabetes. 2018;67(Supplement 1).","DOI":"10.2337\/db18-6-LB"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-019-06852-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-019-06852-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-019-06852-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T16:34:10Z","timestamp":1662914050000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-019-06852-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["6852"],"URL":"https:\/\/doi.org\/10.1007\/s10557-019-06852-6","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"8 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Henry N. Ginsberg has received research grants from Amgen, Merck, Sanofi, and Regeneron Pharmaceuticals, Inc.; and is a consultant on advisory boards for Amgen, Janssen, Lilly, Merck, Novartis, Reserlogix, Sanofi, and Regeneron Pharmaceuticals, Inc. Jaakko Tuomilehto has received research grants from Bayer, Merck, Pfizer, and Sanofi; and has received honoraria and is a consultant on advisory boards for Bayer, Novo Nordisk, and Sanofi. G. Kees Hovingh has received research grants from the Netherlands Organization for Scientific Research, the CardioVascular Research Initiative, and the European Union; has received other research support from Aegerion, Amgen, and Sanofi; has participated in speakers bureau for Amgen, Aegerion, Sanofi, Regeneron Pharmaceuticals, Inc., and Pfizer; and is a consultant on advisory boards for Amgen, Aegerion, Sanofi, Regeneron Pharmaceuticals, Inc., and Pfizer. Bertrand Cariou has received research grants from Sanofi, Regeneron Pharmaceuticals, Inc., and Pfizer; has participated in speakers bureau for Amgen, AstraZeneca, Pierre Fabre, Eli Lilly, Novo Nordisk, MSD, Sanofi, and Regeneron Pharmaceuticals, Inc.; and is a consultant on advisory boards for Amgen, Novo-Nordisk and Sanofi, Regeneron Pharmaceuticals, Inc. Raul D. Santos has received research grants from Amgen and Ionis; has participated in speakers bureau for Amgen, AstraZeneca, Biolab, Sanofi, and Regeneron Pharmaceuticals, Inc.; and is a consultant on advisory boards for Akcea, Amgen, AstraZeneca, Biolab, Kowa, Merck, Novo Nordisk, Sanofi, and Regeneron Pharmaceuticals, Inc. Alan S. Brown has participated in speakers bureau for Amgen, Sanofi, and Regeneron Pharmaceuticals, Inc.; and is a consultant on advisory boards for Amarin, Amgen, Kastle, Kowa, Merck, Pfizer, and Regeneron Pharmaceuticals, Inc. Santosh K. Sanganalmath is an employee of and stockholder in Regeneron Pharmaceuticals, Inc. Andrew Koren is an employee of and stockholder in Sanofi. Desmond Thompson is a consultant to Medical Affairs at Regeneron Pharmaceuticals, Inc. Frederick J. Raal has received research grants from Amgen, Sanofi, and Regeneron Pharmaceuticals, Inc.; participated in speakers bureau for and received honoraria from Amgen, Sanofi, Regeneron Pharmaceuticals, Inc., and the Medicines Company; and is a consultant on advisory boards for Amgen, Sanofi, Regeneron Pharmaceuticals, Inc., and the Medicines Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}